22 federal suits filed over hormone replacement drugs West Virginia Record, WV - Nov 29, 2008 Plaintiffs claim Wyeth is liable because it failed to use due care when it prepared and designed its hormone therapy drugs, failed to perform adequate ...
The Rhythm of the Blues Am J Psychiatry (subscription) - 6 minutes ago (1) reported that patients with bipolar disorder who receive acute treatment with interpersonal and social rhythm therapy show faster improvement in ...
Advances in hormone replacement therapy: making the menopause ... 7thSpace Interactive (press release), NY - Nov 27, 2008 Methods: the importance of the results of some large, randomized controlled trials (RCTs) on Hormone Replacement Therapy (HRT) has modified the risk/benefit ...
Serotonin Enhancing Pharmaceuticals OpEdNews, PA - Norepinepherine is a stress hormone, which many believe help those who have such mood disorders as depression. Basically, with the theory that by adding ...
Learned This Week Vancouver Sun, Canada - Nov 29, 2008 Hormone therapy could accentuate certain pre-existing heart disease risk factors and a heart health evaluation should become the norm when considering ...
Second Opinion Financial Times, UK - By Margaret Mccartney When I was at medical school, hormone replacement therapy was not just the treatment of choice for the flushes and sweats of menopause ...
Source: Google News
Recent News and Articles on the Keywords: hormone therapy + therapy + and Related to the article below (Last Update: 8/7/2008)
Synergism between Oral Estrogen Therapy and Cytochrome P450 3A5*1 ... Journal of Clinical Endocrinology and Metabolism, MD - Context: Hormone therapy increases the risk of venous thromboembolism (VTE) among postmenopausal women. This effect may be modulated by the expression of ...
Treatment of Pituitary Gigantism with the Growth Hormone Receptor ... Journal of Clinical Endocrinology and Metabolism, MD - Objective: The objective of the study was to describe the results of therapy of three children with pituitary gigantism by a GH receptor antagonist, ...
Be careful changing the oil Times Colonist, Canada - Many experts have been pointing the finger at birth control pills and hormone-replacement therapy drugs that get into the water supply. ...
Source: Google News
Hormone therapy to prevent disease and prolong life in postmenopausal women. - D Grady, SM Rubin, DB Petitti, CS Fox, D Black, B … - Ann Intern Med, 1992 - ncbi.nlm.nih.gov ...Hormonetherapy to prevent disease and prolong life in postmenopausal women.
Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger ...
Postmenopausal Hormone Therapy and Mortality. - F Grodstein, MJ Stampfer, GA Colditz, WC Willett, … - Obstetrical & Gynecological Survey, 1997 - obgynsurvey.com November 1997, 52:11 > Postmenopausal HormoneTherapy... ... 697. Postmenopausal HormoneTherapy and Mortality. [Gynecology: Menopause]. ...
Estrogen-progestin menopausal hormone therapy linked to risk of lobular and tubular breast cancer
Estrogen-progestin menopausal hormone therapy is associated with a more than two-fold higher relative risk of developing lobular cancer or tubular cancer than of developing ductal cancer.
The results of a large European study showed for the first time that estrogen-progestin therapy is associated with a higher relative risk of developing tubular cancer than ductal cancer, when taken for more than five years. The study also confirms previous findings that estrogen-progestin therapy is associated with a higher relative risk of lobular cancer than ductal cancer.
Researchers at the Karolinska Institutet in Stockholm, Sweden and colleagues at the Genome Institute of Singapore carried out a population-based case-control study of women recently diagnosed with invasive breast cancer.
They selected 1,888 women with ductal breast cancer, 308 women with lobular cancer and 93 women with tubular breast cancer. All women were matched for age with 3,065 women randomly selected from the population, acting as controls. Both patients and controls were asked to fill in a questionnaire about their medical history, health status and use of menopausal hormone therapy.
Results show that women who used medium potency estrogen-progestin combination therapy had a higher risk of developing lobular or tubular breast cancer than of developing ductal cancer, compared with women who did not use hormone therapy.
The risk of developing any of the cancers was higher for women who had used the therapy for more than five years. For these women, the risk of developing tubular cancer ( OR 6.5 ) or lobular cancer ( OR 5.6 ) was more than twice the risk of developing ductal cancer ( OR 2.3 ).
Other factors, such as the number of births, age at menopause or body mass index, were found to be associated with a similar risk of developing the three subtypes of breast cancer.
